BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/30/2015 2:11:00 PM | Browse: 938 | Download: 885
 |
Received |
|
2014-09-09 08:24 |
|
Peer-Review Started |
|
2014-09-09 14:40 |
|
To Make the First Decision |
|
2014-10-14 17:00 |
|
Return for Revision |
|
2014-10-15 17:19 |
|
Revised |
|
2014-12-22 23:58 |
|
Second Decision |
|
2015-01-08 13:10 |
|
Accepted by Journal Editor-in-Chief |
|
2015-01-10 14:19 |
|
Accepted by Executive Editor-in-Chief |
|
2015-01-16 17:31 |
|
Articles in Press |
|
2015-01-16 18:20 |
 |
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2015-04-07 18:37 |
|
Publish the Manuscript Online |
|
2015-04-20 15:10 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Virology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Scott Bowden, Stephen Locarnini, Ting-Tsung Chang, You-Chen Chao, Kwang-Hyub Han, Robert G Gish, Robert A de Man, Miao Yu, Cyril Llamoso and Hong Tang |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Bristol-Myers Squibb |
|
|
| Corresponding Author |
Scott Bowden, PhD, Victorian Infectious Diseases Reference Laboratory, 792 Elizabeth Street, Melbourne, Victoria 3000, Australia. scott.bowden@mh.org.au |
| Key Words |
Hepatitis B virus; Nucleos(t)ide analog therapy; Intrahepatic hepatitis B virus DNA; Antiviral suppression; Virologic cure |
| Core Tip |
In chronic hepatitis B, persistence of hepatitis B virus (HBV) infection is due to an intrahepatic pool of stable, HBV covalently closed-circular DNA (cccDNA), whose elimination is a limiting factor in anti-HBV treatment. This study shows that 48 weeks of treatment with entecavir resulted in a greater reduction of hepatic HBV cccDNA and total hepatic HBV DNA than lamivudine. However, cccDNA was still detectable in most biopsies, suggesting that despite potent viral suppression with entecavir, prolonged treatment may be needed to eradicate cccDNA. |
| Publish Date |
2015-04-20 15:10 |
| Citation |
Bowden S, Locarnini S, Chang TT, Chao YC, Han KH, Gish RG, de Man RA, Yu M, Llamoso C, Tang H. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World J Gastroenterol 2015; 21(15): 4644-4651 |
| URL |
http://www.wjgnet.com/1007-9327/full/v21/i15/4644.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v21.i15.4644 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
